Wu et al. [47] found that TPM2 can slow the progression of prostate cancer (PCa) by blocking PDLIM7-mediated nuclear translocation of YAP1, suggesting that modulation of TPM2 expression or function may be a potential therapeutic strategy to reduce PCa proliferation and prevent the progression to castration-resistant prostate cancer (CRPC). This evidence concerns the gene YAP1 and prostate carcinoma.